The treatment of all forms of toxoplasmosis is most unsatisfactory and until the reports by Eyles and Coleman (1953) and Summers (1953) the only agents known to have any effect were the sulphonamides. Eyles showed that 2 :4-diamino-pyrimethamines were parasiticidal and that the best of these was probably Daraprim (5-[p-chlorphenyll-2; 4-diamino-6-ethylpyrimidine) . He concluded, however, that it was little more active than the sulphonamides and that they might well be used together [as their actions were complementary. Trevino et aL. (1953) confirmed that the drug was toxoplasmacidal but suggested that there might be strain variation in the susceptibility to Daraprim and a further report by Ryan and others (1954) , that the pyrimethamines were active in cases of human toxoplasmosis of a type which is usually unaffected by sulphonamides, suggested that it would be worth testing the sensitivity of an English strain of the parasite.
Methods.-The mice used were Swiss-Albino of 16-20 grams weight. Mice were infected intracerebrally and received 0-2 mg. Daraprim daily for five days. Daraprim was administered intraperitoneally as a suspension in saline. The results, shown in Table I , are most encouraging, and particularly so in view of the fact that treatment can be delayed until the animals are almost moribund and still one obtains a 50% cure rate; it is worthy of note that if Daraprim is administered so that toxic levels of the drug are reached, folic acid can be given as this appears to decrease the toxicity without decreasing the therapeutic efficiency, an effect first noted by Summers.
Experimental eye lesions.-One of the troubles of any tests of antitoxoplasmic drugs is that we have no good experimental model of the disease seen in the eye; the only animal toxpplasmic chorio-retinitis is seen in the late stage of the disease, in the golden hamster (Frenkel, 1955) . The eye lesions seen in these animals are an incidental event in the fatal systemic disease. We have been working on producing a satisfactory eye lesion and fortunately we have recently discovered a strain (isolated from a fatal human case showing chorioretinitis by Professor C. F. Barwell), which has the great advantage that it is not lethal to rabbits when introduced into the eye. Treatment of these lesions.-Attempts to influence the course of the disease have been made with Daraprim. While the acute iridocyclitis that develops on the third to the fifth days is diminished by Daraprim, there appears to be no effect upon the choroidal lesion whether the drug is given systemically or sub-conjunctivally.
Disappointing results may be, in part, due to the relatively few experiments we have been able to perform, but more probably failure is due to:
(1) Failure of the drug to reach the lesion.
(2) An inadequate systemic dosage-too few experiments.
(3) Differences in the metabolism of the animals. This last needs elaboration, but, briefly, it can be said that it is probable that pyrimethamines act as antagonists in the metabolism of folic acid probably preventing the conversion of folic acid to folinic acid. If this step was not essential in any animal's metabolism, it is possible that the drug would be inactive. Unfortunately, since this paper was written the rabbits which received sub-conjunctival Daraprim have commenced to develop extensive cataractous changes in the lens, pointing to a penetration of the drug into the eye when given sub-conjunctivally. Fortunately, when the drug is given systemically no such cataractous change is seen.
While the results of our treatment of rabbit uveitis were equivocal, the success in the treatment of the mouse infections encouraged us to plan the clinical trial which Mr. Perkins is to describe.
The patients concerned in this trial have been, as far as possible, consecutive cases of active uveitis seen in the Uveitis Clinic at the Institute of Ophthalmology.
The patients all receive a full ophthalmological and general medical examination and a routine pathological examination which includes tests for toxoplasmosis. When patients are considered suitable for inclusion in the trial they are given one of two lots of tablets, according to a list of random numbers, and instructed to take one tablet a day for a month9 after which their condition is reassessed under the following headings: Visual acuity. Aqueous or vitreous flare and cells. Degree of injection. Subjective response. Degree of total objective change. One group of tablets contains Daraprim 25 mg. and the other an inert substance, but the clinician dispensing the tablets and assessing progress does not know which contains the active substance. By this means the psychological effect of the treatment should be equal in all cases.
This report concerns the first 63 cases to complete a full month's trial and for whom pathological reports are complete. Of these cases 30 had an anterior uveitis, 20 a posterior uveitis and 13 a generalized uveitis. It will obviously be necessary at a later date to analyse the results of each anatomical group, comparing toxoplasma-positive and -negative cases, treated and untreated, but if this is done with the present series of 63 cases the numbers in each group are so small as to have little significance. The site of the inflammation has therefore been ignored in the present analysis, and the cases divided into four groups: (1) All cases having a positive dye test titre of 1 : 4 or more who received Daraprim; (2) caseshaving a positive dye test but who received the inert tablets; (3) and (4) treated and untreated cases with negative dye tests.
The results in the four groups are shown in Table I . At first sight it would appear that the results in the first group, the only group in which a response to treatment was likely, are definitely better than those of any other group. However, the number of cases in each group is relatively small and if the figures are tested statistically the results are not so encouraging.
Using the x2 test, a comparison of the first group with any other single group gives results. which could easily be accounted for by chance. If, however, the first group is compared Proceedings of the Royal Society of Medicine 8 with all the other groups combined, the probability that the apparent improvement in the first group is due to chance alone lies between 5 and 10 in 100. While this degree of probability is not sufficient in itself to enable us to say that Daraprim is undoubtedly exerting an influence on the results of uveitis cases treated with it, it certainly does not exclude this possibility. Similarly it is not possible to argue from the results that as there has been an improvement in the toxoplasma-positive cases treated with Daraprim over those with a negative toxoplasma reaction then some of these cases are due to toxoplasmosis, but again this possibility is certainly not excluded by the results, and we feel that it is well worth while to continue the trial, although it may be necessary to modify the dose of drug given. Recent reports have suggested that Daraprim gives good results when given in higher doses; unfortunately it is not free from toxic effects, and in one case in this series treatment had to be stopped on account of a decreasing white cell count, and it seems likely that if higher doses are to be employed the patients will have to be admitted and very carefully controlled during their treatment.
The trial is continuing, but, in addition, all cases with a positive dye test are receiving a course of Daraprim if they have received inert tablets in the trial. I should like to thank Messrs. Burroughs Wellcome & Co. for the supplies of Daraprim tablets for use in this trial.
Dr. Norman Ashton:
In the problem of uveitis we have arrived at a stage where the old etiological concepts no longer appear applicable, either because they were always erroneous, or because, as the President suggests, the disease itself has changed. Many of the old ideas, therefore, are being abandoned, but there is so little new knowledge upon which to base a modern aetiological classification that to-day the subject is beset with confusion and uncertainty. There is an old Basuto proverb which seems remarkably applicable: "If a man does away with his traditional way of living and throws away his good customs, he had better first make certain that he has something of value to replace them."
The limited survey which Dr. Smith and I reported recently (Brit. J. Ophthal., 39, 545, 1955) appears to show that toxoplasmosis is almost certainly an important factor in adult uveitis, particularly in the posterior type, and our findings were in agreement with those of Wilder (Arch. Ophthal., Chicago, 48, 127, 1952) and Woods et al. (Trans. Amer. Acad. Ophthal. Oto-laryng., 58, 172, 1954) . In future studies, I believe we should continue to concentrate on this aspect both in investigation, particularly of unfixed fresh tissues, and in therapeutic trials. The exact role of hypersensitivity in uveitis is exceedingly difficult to define, but it is apparently of great importance, especially in relation to the streptococcus, as shown by anti-streptolysin assays carried out in America and in this country. It has always seemed to me an intriguing problem as to why the uvea, a relatively minute area of vascular tissue presenting few unique histological features, should so peculiarly react in an apparently healthy body. There are, of course, many other examples of such vulnerability; an example would be the specific involvement of glomeruli in acute nephritis and, as in the study of this disease, the fluorescein-antibody conjugation technique of Coons as used by Hill and Cruickshank (Brit. J. exp. Path., 34, 27, 1953) For, although there may be no structural peculiarities, the uvea may well contain distinct cytoplasmic, membranous or stromal elements, which it may be possible to reveal by demonstrating their antigenic component with fluorescein-labelled antibody.
